OSTX
OS Therapies Incorporated1.6200
-0.0500-2.99%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
57.05MP/E (TTM)
-Basic EPS (TTM)
-0.81Dividend Yield
0%Recent Filings
8-K
Raises $7.5M via warrant inducement
OS Therapies inked inducement deals on January 10, 2026, with nine holders to exercise 5.4 million existing warrants at $1.40/share, netting ~$7.5M gross proceeds after fees. New warrants match the count, exercisable at $1.40 for five years. Funds runway into 2027 for OST-HER2 regulatory pushes and OS Animal Health spinoff prep. All offered investors joined.
10-Q
Q3 FY2025 results
OS Therapies posted a Q3 operating loss of $6.9M, up from $2.4M y/y, with R&D expenses tripling to $3.8M on Phase IIb trial data compilation and regulatory prep, while G&A doubled to $3.1M from stock-based comp and services. Nine-month net loss hit $15.3M versus $5.9M y/y, reflecting ramped OST-HER2 efforts post-April asset buy from Ayala for $6.9M fair value (cash/stock mix, recognizing $6.6M patents amortized over 14 years). Cash burned to $1.9M amid $10.5M operating use, offset by $7.3M financing; FCF not disclosed in the 10-Q. Cash dwindles fast. Warrant dilution looms large.
8-K
Stockholders approve expansions
OS Therapies stockholders approved key proposals at the October 21, 2025 annual meeting, electing six directors and ratifying MaloneBailey as auditors. They greenlit the Ayala Issuance for an asset deal, boosted authorized shares to 150 million, and expanded the 2023 Incentive Plan to 10 million shares from 4 million. More equity firepower secured.
8-K
Annual meeting adjourned
OS Therapies adjourned its 2025 annual meeting on October 14 after three key proposals—stock issuance, charter amendment, and auditor ratification—passed preliminary votes, reconvening October 21 to solicit more proxies. Investor presentation posted October 17 highlights OST-HER2's positive Phase 2b data in osteosarcoma, targeting FDA accelerated approval Q2/Q3 2026 and $160M PRV. Cash lasts mid-2026. Meeting adjournment signals proxy battle.
8-K
Prospectus for 4.4M share resale
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
FATE
Fate Therapeutics, Inc.
1.09-0.03
GRCE
Grace Therapeutics, Inc.
3.34+0.10
GTBP
GT Biopharma, Inc.
0.72+0.09
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MRKR
Marker Therapeutics, Inc.
1.27-0.12
ORGS
Orgenesis, Inc.
0.15-0.01
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OSRH
OSR Holdings, Inc.
0.55-0.02
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00